UBS resumed coverage of Sanofi with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2025 | $65.00 | Outperform | Exane BNP Paribas |
| 3/21/2025 | $65.00 | Neutral | Goldman |
| 1/30/2025 | Sell → Hold | Deutsche Bank | |
| 7/26/2024 | $55.00 → $60.00 | Buy | Argus |
| 1/23/2024 | $55.00 | Equal-Weight | Morgan Stanley |
| 1/16/2024 | Buy | UBS | |
| 12/5/2023 | Overweight → Neutral | JP Morgan | |
| 10/30/2023 | Buy → Hold | Stifel |
Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00
Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00
Deutsche Bank upgraded Sanofi from Sell to Hold